Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNASDAQ:THOR
CUSIP88517530
Phone+1-925-8478600
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins10.29%
Return on Equity8.02%
Return on Assets6.71%
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Thoratec (NASDAQ:THOR) Frequently Asked Questions
What is Thoratec's stock symbol?
Thoratec trades on the NASDAQ under the ticker symbol "THOR."
How were Thoratec's earnings last quarter?
Thoratec Co. (NASDAQ:THOR) issued its quarterly earnings data on Tuesday, August, 4th. The medical instruments supplier reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.09. The medical instruments supplier earned $128.70 million during the quarter, compared to analyst estimates of $115.48 million. Thoratec had a return on equity of 8.02% and a net margin of 10.29%. Thoratec's quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.43 EPS. View Thoratec's Earnings History.
Has Thoratec been receiving favorable news coverage?
News stories about THOR stock have trended somewhat positive on Friday, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Thoratec earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 45.93 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Thoratec?
Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Thoratec?
Thoratec's mailing address is 6035 Stoneridge Dr, PLEASANTON, CA 94588, United States. The medical instruments supplier can be reached via phone at +1-925-8478600.
MarketBeat Community Rating for Thoratec (THOR)
MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
